Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Abstract excerpt

Prostacyclin (PGI2) is a potent vasodilator and important mediator of vascular homeostasis; however, its clinical use is limited because of its short (<2-min) half-life. Thus, we hypothesize that the use of engineered endothelial progenitor cells (EPCs) that constitutively secrete high levels of PGI2 may overcome this limitation of PGI2 therapy. A cDNA encoding COX-1-10aa-PGIS, which links human cyclooxygenase-1...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Growth Processes
• Share to Culture Media, Conditioned